

Flexion Therapeutics Inc
Form SC 13G/A
February 15, 2019

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G/A

(RULE 13d - 102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND
AMENDMENTS THERETO FILED PURSUANT TO 13d-2

(Amendment No. 7)*

Flexion Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value \$0.001

(Title of Class of Securities)

33938J106

(CUSIP Number)

December 31, 2018

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(Page 1 of 5 Pages)

CUSIP No. 33938J106

NAME OF REPORTING PERSON

1
Gilder, Gagnon, Howe & Co. LLC

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) "
2
(b) "

SEC USE ONLY

3
CITIZENSHIP OR PLACE OF ORGANIZATION

4
New York

SOLE VOTING POWER

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5M3,783
SHARED VOTING POWER
6H
SOLE DISPOSITIVE POWER
753,783
8 SHARED DISPOSITIVE POWER
J,336,177

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

9 1,389,960

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

10 ..

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

116.31%

TYPE OF REPORTING PERSON

12 BD

Explanatory Note

This amendment is an amendment to the Schedule 13G/A of Gilder, Gagnon, Howe & Co. LLC (the “Company”) filed on February 14, 2019 (the “Original 13G/A”). In the Original 13G/A, the Company inadvertently included the incorrect signatory on the signature page. This Schedule 13G/A amends the Original 13G/A for the sole purpose of including the correct signatory on the signature page. Other than as described in this Explanatory Note, this Schedule 13G/A is identical to the Original 13G/A. This 13G/A speaks as of the original filing date of the Original 13G/A, does not reflect events that may have occurred subsequent to the original filing date, and does not modify or update in any way disclosures made in the Original 13G/A.

ITEM 1(a).

Name of Issuer:

Flexion Therapeutics, Inc.

Item 1(b).

Address of Issuer's Principal Executive Offices:

10 Mall Road Suite 301
Burlington, MA 01803

Item 2(a).

Name of Persons Filing:

Gilder, Gagnon, Howe & Co. LLC

Item 2(b).

Address of Principal Business Office or, if None, Residence:

475 10th Avenue
New York, NY 10018

Item 2(c).

Citizenship:

New York

Item 2(d).

Title of Class of Securities

Common Stock

Item 2(e).

CUSIP Number:

33938J106

ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULE 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

- (a) Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
- (b) Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
- (c) Insurance company defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
- (d) Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
- (e) An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
- (f) An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
- (g) A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
- (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
- (i) A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J)
- (k) Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned: 2,389,960

(b) Percent of class: 6.31%

(c) Number of shares of Common Stock as to which such person has:

(i) Sole power to vote or direct the vote: 53,783

(ii) Shared power to vote or direct the vote: 0

(iii) Sole power to dispose or direct the disposition: 53,783

(iv) Shared power to dispose or direct the disposition: 2,336,177

The shares reported include 2,191,426 shares held in customer accounts over which partners and/or employees of the Reporting Person have discretionary authority to dispose of or direct the disposition of the shares, 53,783 shares held in the account of the profit sharing plan of the Reporting Person, and 144,751 shares held in accounts owned by the partners of the Reporting Person and their families.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following "":

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certification.

By signing below the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

SIGNATURES

After reasonable inquiry and to the best of the undersigned's knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: February 13, 2019

GILDER, GAGNON, HOWE &
CO. LLC

By: /s/ Laura M. Esposito
Name: Laura M. Esposito
Title: Chief Compliance Officer